MARKET

ESPR

ESPR

Esperion Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

50.13
-0.16
-0.32%
After Hours: 50.13 0 0.00% 16:47 12/11 EST
OPEN
50.24
PREV CLOSE
50.29
HIGH
50.54
LOW
49.32
VOLUME
504.48K
TURNOVER
--
52 WEEK HIGH
55.70
52 WEEK LOW
33.13
MARKET CAP
1.37B
P/E (TTM)
-13.5696
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ESPR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ESPR News

  • Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue?
  • Zacks.5d ago
  • Can Cannabis 2.0 Kickstart Marijuana Stocks?
  • MotleyFool.com.5d ago
  • Esperion's Promising Drugs Under Review, Funds a Concern
  • Zacks.11/28 12:09
  • Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • GlobeNewswire.11/22 23:30

More

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About ESPR

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.
More

Webull offers Esperion Therapeutics Inc (ESPR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.